Clinical Trial Results - Moleculin reported a preliminary blinded complete remission composite (CRc) rate of 40% in the first 30 subjects treated in the MIRACLE trial, consisting of a 30% complete remission (CR) rate and a 10% complete remission with partial hematological recovery (CRh) rate[5]. - The MIRACLE trial is expected to unblind data for 45 subjects in mid-2026, with a total of 222 additional subjects to be randomized in Part B of the trial[9][7]. - Approximately 35% of subjects treated to date in the MIRACLE trial are relapsed or refractory from a venetoclax regimen, indicating a challenging patient population[5]. Financial Performance - The company reported a net loss of $33.6 million for the year ended December 31, 2025, compared to a net loss of $26.0 million in 2024, with a net loss per common share of $28.42[23]. - Research and development (R&D) expenses for the year ended December 31, 2025, were $15.9 million, a decrease of $1.8 million from $17.7 million in 2024, primarily due to reduced sponsored research activities[13]. - General and administrative (G&A) expenses increased to $9.2 million in 2025 from $8.9 million in 2024, attributed to higher regulatory, legal, consulting, and investor relations expenses[14]. Assets and Liabilities - As of December 31, 2025, the company had cash and cash equivalents of $8.9 million, with total current assets amounting to $9.7 million, an increase from $5.2 million in 2024[15][23]. - Moleculin's total assets as of December 31, 2025, were $22.1 million, up from $16.9 million in 2024, while total liabilities increased to $7.1 million from $5.7 million[23]. Future Plans - The company anticipates starting a Phase 1B/2 study of Annamycin in third-line pancreatic cancer in the second half of 2026[9][10]. - The company has entered a new research collaboration focused on glioblastoma multiforme (GBM) to evaluate intra-arterial delivery of Annamycin in preclinical models[6].

Financial Performance - Net income attributable to common stockholders decreased by $2.9 million to $1.6 million ($0.06/share) in Q4 2025, compared to $4.5 million ($0.17/share) in Q4 2024[6] - Revenues and other income increased 8% to $23.3 million in Q4 2025, up from $21.6 million in Q4 2024[6] - Total revenues for the three months ended December 31, 2025, increased to $21,106,000, up from $17,935,000 in the same period of 2024, representing a growth of 12.1%[30] - Net income attributable to common stockholders for the three months ended December 31, 2025, was $1,581,000, compared to $4,483,000 in the same period of 2024, reflecting a decrease of 64.8%[30] - The company reported an operating loss of $2,292,000 for the three months ended December 31, 2025, compared to a loss of $2,126,000 in the same period of 2024[30] - Total expenses for the three months ended December 31, 2025, were $18,814,000, up from $15,809,000 in the same period of 2024, marking an increase of 18.9%[30] - The company incurred a stock compensation expense of $554,000 for the three months ended December 31, 2025, compared to $96,000 in the same period of 2024[35] - Investment income for the three months ended December 31, 2025, was $165,000, down from $430,000 in the same period of 2024, a decline of 61.7%[30] - The company’s total other income, net for the three months ended December 31, 2025, was $90,000, compared to $348,000 in the same period of 2024, a decrease of 74.1%[30] Farming Segment Performance - Farming segment revenues increased 26% to $12.2 million in Q4 2025, compared to $9.7 million in Q4 2024[6] - Farming segment revenues increased 34.6% to $18.7 million in 2025, driven by a return of pistachio production contributing $5.3 million[16] - For the three months ended December 31, 2025, farming revenues increased to $12,240,000, up from $9,676,000 in the same period of 2024, representing a growth of 26%[44] - Adjusted EBITDA for the farming segment reached $3,804,000 for the three months ended December 31, 2025, compared to $2,676,000 in the same period of 2024, reflecting a 42% increase[44] - The adjusted farming EBITDA before fixed water obligations was $4,428,000 for the three months ended December 31, 2025, compared to $3,429,000 in the same period of 2024, indicating a 29% increase[44] - The company's fixed water obligations for the farming segment were $624,000 for the three months ended December 31, 2025, down from $753,000 in the same period of 2024[44] Capital and Liquidity - Total capital, including debt, was $584.5 million as of December 31, 2025, with total liquidity of approximately $91.0 million[13] Operational Developments - The TRCC industrial portfolio is 100% leased, comprising 2.8 million square feet of gross leasable area[10] - The construction of the Nestlé USA distribution facility, over 700,000 square feet, has been completed and is preparing to become operational[11] Future Outlook - The Company expects net income to fluctuate based on development activity, commodity prices, and timing of land sales[15] - The Company planted 150 acres of olives in 2025 and plans to plant an additional 150 acres in 2026 as part of its crop diversification strategy[18] Shareholder Information - Basic and diluted earnings per share for the three months ended December 31, 2025, were both $0.06, consistent with the previous quarter[46] - The period-end share price was $15.77, a slight decrease from $15.98 in the previous quarter[46] - The weighted average number of diluted shares outstanding for the three months ended December 31, 2025, was 26,965,558, compared to 26,829,344 in the same period of 2024[30] - The weighted average shares outstanding increased to 26,907,329 for the three months ended December 31, 2025, compared to 26,890,979 in the previous quarter[46] Debt and Interest - The company reported a total interest expense of $3,892,000, with a significant portion attributed to unconsolidated joint ventures[39] - The company's share of equity in earnings of unconsolidated joint ventures for the year ended December 31, 2025, was $8,362,000, down from $10,881,000 in 2024, a decrease of 23.1%[30] Depreciation and Amortization - The total depreciation and amortization for the company was $11,638,000, with $4,885,000 attributed to consolidated operations[39]

Clinical Development and Trials - TSHA-102 is in clinical development for Rett syndrome, with a focus on addressing severe unmet medical needs in patients aged 2 years and older[1]. - A total of 12 patients have been dosed in Part A of the REVEAL trials, with positive clinical data reported showing that the first 10 patients gained or regained developmental milestones[20]. - The REVEAL pivotal trial will enroll 15 females aged 6 to <22 years, with a low likelihood (0% to <6.7%) of gaining new developmental milestones[22]. - The ASPIRE trial will enroll three females aged 2 to <4 years to evaluate the safety and preliminary efficacy of TSHA-102, with dosing expected to be completed in the second quarter of 2026[24]. - The REVEAL pivotal trial protocol has been aligned with the FDA, including a 6-month interim analysis that may support a biologics license application (BLA) submission[23]. - The REVEAL pivotal trial will enroll 15 females aged 6 to <22 years, with a minimum success threshold of a 33% response rate (5 out of 15 patients) for developmental milestones[43]. - A total of 100% of patients in the high dose cohort (N=6) gained or regained developmental milestones post-TSHA-102 treatment, compared to a 0% likelihood without treatment[49]. - The high dose cohort achieved a 100% responder rate by 12 months, with a 75% responder rate at 6 months[60]. - A total of 165 additional skills and improvements were achieved across 10 patients, supporting the broad therapeutic impact of TSHA-102[55]. - The average R-MBA score improvement post-TSHA-102 was -12.2 for the high dose cohort at 6 months, compared to -9.8 for the low dose cohort[60]. - No treatment-related serious adverse events were reported among 12 patients aged 6-21 years, indicating good tolerability of TSHA-102[61]. - The REVEAL pivotal trial is expected to complete patient dosing by Q2 2026, with interim analysis potentially expediting the BLA submission by at least two quarters[47]. - The ASPIRE trial is underway to evaluate the safety and preliminary efficacy of TSHA-102 in younger patients aged 2 to <4 years, with dosing expected to complete in Q2 2026[48]. Regulatory Designations and Approvals - The FDA has granted Breakthrough Therapy designation to TSHA-102 based on positive clinical evidence from 12 patients treated in Part A of the REVEAL trials[27]. - The company has received orphan drug designation and rare pediatric disease designation from the FDA for TSHA-102, as well as Fast Track Designation[26]. - The FDA provided written alignment on key elements of the REVEAL pivotal trial design, enabling a potential BLA submission for TSHA-102[42]. - The company plans to initiate a Process Performance Qualification campaign in the second quarter of 2026 to support the BLA submission for TSHA-102[25]. - The FDA requires extensive preclinical and clinical testing before biological product candidates can be marketed, including submission of an IND application[98]. - The BLA submission process includes a 60-day review period by the FDA to determine if the application is complete for substantive review[105]. - The FDA aims to review standard BLA applications within 10 months and priority applications within 6 months after acceptance[106]. - The RMAT program aims to expedite the development and review of regenerative medicine therapies intended to treat serious diseases, potentially allowing for priority review or accelerated approval[112]. - A product eligible for priority review must show significant improvement in treating serious conditions, with the FDA aiming to act on applications within six months of filing[114]. - Accelerated approval may be granted based on effects on surrogate endpoints likely to predict clinical benefits, with post-marketing studies required to verify these effects[115]. - Orphan Drug Designation can be granted for drugs treating rare diseases affecting fewer than 200,000 individuals in the U.S., providing seven years of exclusivity upon first approval[118]. - The FDA may withdraw approval if regulatory compliance is not maintained, which could lead to product recalls or additional studies[122]. Financial Overview - The company incurred net losses of $109.0 million and $89.3 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $711.3 million as of December 31, 2025[189]. - The company has financed operations with $961.0 million in gross proceeds from equity financings, including pre-IPO private placements and public offerings[189]. - All product candidates are in preclinical or clinical development, with no products approved for commercialization and no revenue generated from product sales to date[190]. - The company expects to incur significant expenses and operating losses over the next several years, with expenses anticipated to increase substantially as it advances its product candidates[190]. - As of December 31, 2025, the company had cash and cash equivalents of $319.8 million, which is expected to fund operations into 2028[197]. - The company may require additional capital to achieve its business objectives, and unfavorable global economic conditions could adversely affect its ability to raise such capital[198]. - The company’s existing indebtedness contains restrictions that may limit operational flexibility and could lead to an event of default if certain conditions are not met[199]. - The company does not expect to generate revenue from its product candidates for several years, if at all, and the success of TSHA-102 will depend on various factors including regulatory approval and market acceptance[212]. Intellectual Property and Collaborations - The company entered into a license agreement with Abeona for Rett syndrome, involving a one-time upfront fee of $3.0 million and potential milestone payments totaling up to $56.5 million per licensed product[81]. - The Abeona Rett Agreement triggered a regulatory milestone payment of $1.0 million upon CTA filing approval in March 2022, and a $3.5 million payment after dosing the first patient in May 2023[82]. - The company has in-licensed six U.S. patents and 13 foreign patents as of January 22, 2026, to protect its proprietary technology in gene therapy[89]. - The company has sub-licensed 9 pending patent applications worldwide for feedback-enabled synthetic genes aimed at treating Rett Syndrome, with patents expected to expire in 2039[92]. - The company owns two pending U.S. provisional patent applications for assessing the severity of Rett Syndrome, with expected patent expiration in 2046[93]. - The company in-licenses 5 pending patent applications for RNA interference constructs targeting MAPT for Tauopathies, with patents expected to expire in 2042[94]. - The company in-licenses 3 pending patent applications for FMR1-encoding transgene packaged in an AAV vector for treating Fragile X Syndrome, with patents expected to expire in 2043[95]. - The company has a research collaboration with UT Southwestern, which includes a royalty-free license for certain patent rights and know-how, with no future milestone obligations[76][77]. - The Option Agreement with Astellas expired in October 2025 without exercise, allowing the company to regain full rights to TSHA-102[85]. Market and Competitive Landscape - The company may face significant competition from other biotechnology and pharmaceutical companies, which could adversely affect its operating results[190]. - The company has a pipeline of early-stage gene therapy programs targeting CNS diseases for future development or partnerships[62]. - TSHA-113 is being developed for tauopathies, affecting an estimated 11,000 patients in the U.S. and Europe, including Alzheimer's disease, which impacts approximately 6.2 million Americans and 7.8 million Europeans[63][65]. - TSHA-113 demonstrated significant reduction in tau mRNA and protein levels in PS19 mice, with treatment improving survival rates and alleviating symptoms of neurodegeneration[68]. - TSHA-114 is under development for Fragile X syndrome, which affects about 75,000 patients in the U.S. and Europe, characterized by cognitive impairment and behavioral issues[73][69]. - TSHA-114 showed robust FMRP expression and normalization of hyperactivity and sleep in treated Fmr1 KO mice, supporting its continued development[71][72]. Regulatory Challenges and Compliance - The regulatory approval processes for product candidates are lengthy and unpredictable, which could significantly impact the company's business[187]. - The company must comply with varying international regulatory requirements for marketing products outside the U.S., which may differ significantly from FDA processes[129]. - The maximum evaluation timeframe for a Marketing Authorization Application (MAA) under the centralized procedure is 210 days, which can be reduced to 150 days for accelerated assessments[135]. - The decentralized MAA procedure requires a separate application to each EU Member State, with a draft assessment prepared within 120 days[136]. - Innovative products targeting unmet medical needs may be eligible for expedited development programs like the Priority Medicines (PRIME) scheme, enhancing regulatory support[139]. - A conditional Marketing Authorization (MA) can be granted for products lacking complete safety and efficacy data, valid for one year and renewable annually until conditions are fulfilled[141]. - The EU provides eight years of data exclusivity and ten years of market exclusivity for innovative medicinal products post-MAA, with potential extensions for new therapeutic indications[147]. - Orphan medicinal products receive a ten-year market exclusivity period, which can be extended by two years if a Pediatric Investigation Plan (PIP) is complied with[151]. - The market exclusivity period may be reduced to six years if the product no longer meets orphan criteria or if it is sufficiently profitable[153]. - MA holders must establish a pharmacovigilance system and comply with regulatory obligations, including expedited reporting of serious adverse reactions[154]. - New MAAs must include a risk management plan (RMP) detailing the risk management system and measures to minimize associated risks[155]. - The company is subject to various healthcare regulations, including the U.S. federal Anti-Kickback Statute and the civil False Claims Act, which impose strict compliance requirements on promotional activities and claims for payment[158]. - The company faces significant uncertainty regarding the coverage and reimbursement status of its pharmaceutical products, which can vary widely among third-party payors[164]. - The U.S. Department of Health and Human Services imposes rebates on Medicare products to penalize price increases that exceed inflation, impacting the company's pricing strategies[168]. - The company must navigate complex pricing negotiations in the European Union, where pricing and reimbursement schemes differ significantly across member states[169]. - The Affordable Care Act (ACA) has substantially changed the financing of healthcare in the U.S., affecting the pharmaceutical industry through new rebate methodologies and annual fees[171]. - Recent legislative changes, such as the One Big Beautiful Bill Act, are expected to reduce Medicaid spending and enrollment, potentially impacting the company's market[171]. - The current administration's policies aim to reduce drug prices through initiatives like Most-Favored Nation pricing, which could affect the company's profitability and operational costs[172]. - The company may face increased compliance risks due to proposed changes in regulations affecting drug pricing and marketing practices[172]. - The company is required to report payments and transfers of value to healthcare professionals under the U.S. federal Physician Payments Sunshine Act, impacting its marketing strategies[162]. - The company must conduct clinical studies to demonstrate cost-effectiveness for pricing negotiations in various countries, which could delay commercialization efforts[169]. Future Outlook and Challenges - The company aims to advance the preclinical and clinical development of its product candidates and establish a commercialization infrastructure[191]. - The company has a limited operating history since its inception in 2019, making it difficult for investors to evaluate its future viability[194]. - The company may face significant delays or challenges in achieving sustainable production of its product candidates, impacting commercialization efforts[215]. - The regulatory landscape for gene therapy products is complex, uncertain, and subject to change, making it difficult for the company to predict the time and cost of obtaining regulatory approval for product candidates[216]. - Very few therapeutic products in the genetic medicine field have received marketing authorization from the FDA or the European Commission[216]. - Regulatory requirements for gene therapy and cell therapy products have changed frequently and are expected to continue evolving in the future[216]. - There is substantial overlap in the regulatory bodies responsible for existing gene therapy and cell therapy products[216].

Financial Performance - For the year ended December 31, 2025, WPP plc reported revenue of £13,550 million and operating profit of £382 million[24]. - Revenue for 2025 decreased to £13,550 million, down 8% from £14,741 million in 2024[64]. - Operating profit fell to £382 million, a decline of 71% compared to £1,325 million in 2024[64]. - The loss for the year was £172 million, representing a 127.3% decrease from a profit of £629 million in 2024[64]. - Net cash inflow from operating activities dropped to £724 million, down 49% from £1,408 million in 2024[64]. - Headline PBT for 2025 was £1,086 million, down 26% from £1,467 million in 2024[92]. - Headline operating profit for 2025 was £1,360 million, a decrease of 22% from £1,747 million in 2024[88]. - Like-for-like revenue growth for 2025 was reported at -3.6%, compared to a growth of 2.3% in 2024[81]. - The company reported a significant goodwill impairment of £641 million for 2025, compared to £237 million in 2024[91]. - Adjusted free cash flow significantly decreased to £202 million in 2025, compared to £738 million in 2024, a drop of 72.6%[102]. Employee and Operational Metrics - The Group had 98,655 employees as of December 31, 2025[24]. - The Company employs approximately 98,655 people and has a presence in over 100 countries[38]. - The Company had approximately 73,000 employees based in 49 campuses as of December 31, 2025, compared to 68,000 in 47 campuses in 2024[58]. - WPP is reliant on third parties for significant portions of its IT and operations, which poses risks to operational performance[31]. - The Company is highly dependent on the talent and skills of its employees, with a focus on maintaining effective risk management and compliance frameworks[134]. - The Company has established reputations in the industry that attract talented personnel, but faces competition for key employees[134]. Client and Market Dynamics - The ten largest clients accounted for 21.4% of net sales in the year ended December 31, 2025[34]. - Economic risks, including inflation and currency volatility, could lead clients to reduce or cancel spending, impacting revenues[29]. - Geopolitical tensions may cause clients to scale back or delay marketing budgets, affecting overall business confidence[29]. - The failure to execute the strategic plan published in February 2026 could adversely affect market share and long-term value[30]. Financial Liabilities and Debt Management - The Company has issued $220 million of 5.625% bonds due November 2043, with WPP plc as the parent guarantor[68]. - Adjusted net debt improved to £(2,167) million in 2025 from £(1,742) million in 2024, indicating a reduction in net debt levels[105]. - Average adjusted net debt decreased to £(3,404) million in 2025 from £(3,506) million in 2024, reflecting a positive trend in debt management[105]. - The company has issued US$300 million 5.125% guaranteed senior notes due September 2042, with a repurchase of US$28.4 million in 2018 and US$178.7 million in 2019[158]. - The company has EUR 750 million 2.250% guaranteed senior notes due September 2026, listed on the Global Exchange Market of the Irish Stock Exchange[159]. Regulatory and Compliance Risks - The company faces risks related to data privacy and compliance with evolving regulations, which could lead to legal and financial repercussions[34]. - Cybersecurity threats have increased, with potential impacts on operations and client trust if data is compromised[34]. - Changes in local or international tax rules could expose WPP to significant additional tax liabilities, affecting liquidity[34]. - The Company is subject to potential increased costs due to future changes in ESG laws and regulations, including carbon offset pricing[37]. Shareholder Information - Major shareholders include BlackRock Inc. with 9.84% ownership, FIL Limited at 8.92%, and Mondrian Investment Partners at 5.63%[139]. - As of December 31, 2025, the total number of outstanding ordinary shares was 1,078,802,358, with 50.5% held by US residents[140]. - The geographic distribution of share ownership shows 28.6% in the United Kingdom, 50.5% in the United States, and 20.9% in the rest of the world[140]. Internal Controls and Audit - The Company has evaluated its disclosure controls and procedures as of December 31, 2025, concluding they were effective[218]. - Management assessed the effectiveness of internal control over financial reporting as of December 31, 2025, and found it to be effective[219]. - The Company's internal control over financial reporting was audited by PwC, confirming its effectiveness[220]. - There were no changes in the Company's internal control over financial reporting during 2025 that materially affected its effectiveness[221]. - The Audit Committee includes financial experts, with Sandrine Dufour identified as the financial expert under the Sarbanes-Oxley Act 2002[222].

Product Approval and Market Launch - Humacyte's Symvess® (ATEV) received FDA approval in December 2024 for treating extremity vascular trauma, with a market launch expected in 2025[9]. - The company has established commercial-scale manufacturing with an annual capacity of up to 40,000 ATEVs[9]. - The current price point for Symvess is $17,000, making it the second most cost-effective option after saphenous vein grafts, resulting in a net cost reduction of $104,573[49]. - The anticipated milestones for 2026 include the U.S. commercial launch of CABG (CTEV) and the publication of Phase 3 results for the V007 dialysis study[137]. Clinical Performance and Safety - In clinical studies, Symvess demonstrated a primary patency rate of 87.1% and a secondary patency rate of 91.5%, compared to 78.9% for synthetic grafts[36]. - The conduit infection rate for Symvess was 0.9%, significantly lower than the 8.4% rate for synthetic grafts[36]. - The amputation rate for patients using Symvess was 4.5%, compared to 24.3% for synthetic grafts[36]. - ATEV demonstrated a functional patency of 81.3% at 6 months compared to 66.4% for autogenous fistula (AVF), indicating superior performance[60]. - In the V007 trial, ATEV showed a secondary patency rate of 68.3% at 12 months, outperforming AVF at 62.2%[60]. - ATEV has shown no increased safety events per year of usability in the expected target population, with treatment emergent adverse events at 96.3% for ATEV compared to 98.2% for AVF[64]. - The ATEV was successfully used in a 70-year-old patient with severe vascular disease, showing a patent ATEV without significant stenosis at the distal anastomosis after one year[88]. Strategic Partnerships and Market Focus - The company has a strategic partnership with Fresenius Medical Care Holdings, Inc. for marketing and distribution of its 6 millimeter ATEV in specified markets[1]. - Humacyte's technology aims to address major drawbacks of current treatment options for vascular injuries, providing a definitive and permanent repair solution[35]. - The company is focused on expanding its product offerings through its bioengineering platform, which enables the development of a broad range of regenerative medicine products[11]. - The company is focused on addressing unmet needs in multiple markets, including vascular trauma and peripheral arterial disease, through its bioengineering platform[139]. Financial Impact and Market Potential - Symvess is associated with a potential savings of $40,705 per patient compared to synthetic grafts, with infection charges per synthetic graft at $8,848 versus $589,921 for vascular graft infections[47]. - The total addressable market (TAM) for Symvess in the U.S. vascular trauma market is estimated at 26,000 patients, with 18,667 being emergent vascular trauma cases[42]. Future Developments and Innovations - Humacyte's pipeline includes multiple potential commercial launches, with ongoing Phase 3 trials for various applications[17]. - The company plans to launch the Coronary Tissue Engineered Vessel (CTEV) for Coronary Artery Bypass Grafting (CABG) in the U.S. and expand into international markets[134]. - The BioVascular Pancreas (BVP) demonstrated a 100% cure rate for diabetes in a rat model, with all animals showing normalized blood glucose levels[123]. - Over 80% islet retention was observed at 2 months in non-human primate studies, indicating superior islet survival compared to existing transplantation methods[125]. - The BVP is designed to deliver pancreatic islets while promoting neovascularization and long-term islet survival, addressing significant drawbacks of current islet transplantation methods[108]. - The company operates 8 LUNA200 systems, with an annual capacity expected to exceed 40,000 ATEVs, supporting commercial manufacturing scale[135]. - The CTEV showed positive patency results in animal models, with no significant stenosis or adverse events reported during the study duration[104]. Demographic Insights - The analysis of hemodialysis patients indicates that women have a 90% increased risk of complications with AVG ± CVC access compared to men, highlighting a significant unmet need in this demographic[57]. - The V012 trial aims to compare ATEV to AVF in female patients, with a target enrollment of 150 subjects and an interim analysis planned after 80 patients[70]. Military Applications - The Department of Defense (DoD) has designated Symvess as a "Priority Product," with funding for its development and evaluation in battlefield injuries, achieving a 100% limb salvage rate in Ukrainian warfighters[51].

Financial Performance and Market Risks - Signet's share price may experience significant volatility due to fluctuations in financial results and market conditions, potentially impacting investment value [187]. - The company provides public guidance on expected sales and operating results, which may not be met, leading to potential declines in stock price if actual results fall short [188]. - A material deterioration in financial performance could breach borrowing covenants, necessitating renegotiation with lenders or alternative financing sources [191]. - The company is subject to various legal proceedings and regulatory investigations, which could negatively impact earnings, cash flow, and management focus [200]. - Changes in tax laws and regulations, including the Bermuda Corporate Income Tax Act of 2023, could adversely affect the company's effective tax rate and financial results [204]. Liquidity and Operational Risks - Signet's primary sources of liquidity include cash on hand, operational cash flow, and an asset-based credit facility, which are crucial for sustaining operations, especially during seasonal fluctuations [190]. - Collective bargaining agreements could lead to labor disruptions, increasing costs and negatively impacting operations [199]. - The company's ability to attract and retain qualified talent is critical for sales and earnings, with potential risks from labor market competition and leadership transitions [194]. International Operations and Currency Risks - Signet's global operations are impacted by international laws, foreign taxes, and potential shipping disruptions, which could affect sourcing and manufacturing [206]. - Signet's total assets were approximately 90% held in entities with a functional currency of US dollars, and about 91% of its sales were generated in US dollars for Fiscal 2026 [347]. - In Fiscal 2026, approximately 28% of the International reportable segment's goods purchased were transacted in US dollars, down from 31% in Fiscal 2025 [349]. - The company uses derivative financial instruments to hedge against foreign currency exchange rate risks, including forward foreign currency exchange contracts and commodity forward purchase contracts [346]. - The sensitivity analysis indicated that a 10% depreciation of the US dollar against the British pound could result in a fair value loss of $1.5 million for foreign exchange contracts [354]. - Signet's results are subject to fluctuations in the cost of diamonds, gold, and other precious metals, which are key components of its products [351]. - The company aims to minimize net foreign exchange exposure through managing cash levels and utilizing foreign currency exchange contracts and swaps [350]. - As of January 31, 2026, the fair value of derivative financial instruments is based on market value equivalents, considering current foreign currency and commodity forward rates [356]. Risk Management - The Finance Committee of the Board is responsible for monitoring market and liquidity risk within the company's treasury policies [344]. - Signet's exposure to market risk is managed by senior management, with certain derivative instruments requiring review and approval by the CFO [345].

Financial Performance - Taysha Gene Therapies reported a net loss of $109.0 million for the year ended December 31, 2025, compared to a net loss of $89.3 million for 2024, representing an increase in loss of approximately 22%[10] - Taysha's revenue for the year ended December 31, 2025, was $9.8 million, an increase from $8.3 million in 2024[20] - The accumulated deficit widened to $(711.30) million in 2025 from $(602.31) million in 2024, indicating a decrease in financial health[22] Expenses - Research and development expenses increased to $86.4 million in 2025 from $66.0 million in 2024, primarily due to higher compensation expenses and clinical trial activities[8] - General and administrative expenses rose to $33.9 million in 2025 from $29.0 million in 2024, driven by increased compensation and legal fees[9] Cash and Assets - Taysha had $319.8 million in cash and cash equivalents as of December 31, 2025, with expectations to fund operations into 2028[11] - Total assets increased to $343.32 million in 2025 from $160.36 million in 2024, representing a growth of 114%[22] - Cash and cash equivalents rose significantly to $319.77 million in 2025, up from $139.04 million in 2024, marking an increase of 130%[22] - Total stockholders' equity surged to $246.94 million in 2025, compared to $71.53 million in 2024, reflecting a growth of 245%[22] - Additional paid-in capital grew to $958.43 million in 2025, up from $677.86 million in 2024, an increase of 41.4%[22] Liabilities - Current liabilities slightly increased to $26.55 million in 2025 from $26.23 million in 2024, a rise of 1.3%[22] - Accounts payable rose to $6.28 million in 2025 from $3.59 million in 2024, an increase of 74.8%[22] - Term loan, net increased to $50.11 million in 2025 from $43.94 million in 2024, a rise of 14.9%[22] Clinical Trials and Product Development - The company dosed multiple patients in the REVEAL pivotal trial and is on track to complete dosing in both the REVEAL and ASPIRE trials by Q2 2026[4] - Taysha received FDA clearance to initiate the ASPIRE trial, which will include safety data for patients aged 2 to <4 years in the planned BLA submission[6] - The anticipated demand for TSHA-102 is supported by market research indicating strong interest from clinicians and caregivers for treating 6,000 to 9,000 patients with Rett syndrome in the U.S.[13] - The company expects to complete dosing in the REVEAL pivotal trial and the ASPIRE trial in the second quarter of 2026, with longer-term safety and efficacy data expected to be released around the same time[13] Asset Changes - Property, plant and equipment decreased to $6.74 million in 2025 from $7.49 million in 2024, a decline of 10.1%[22] - Operating lease right-of-use assets increased to $9.44 million in 2025 from $8.38 million in 2024, a growth of 12.6%[22] - The company has maintained a favorable tolerability profile for TSHA-102, with no treatment-related serious adverse events reported as of March 2026[6]

Financial Performance - Fourth quarter 2025 net income of $7.8 million improved by $13.4 million compared to a net loss of $5.6 million in the prior year[4] - Net sales for the fourth quarter were $215.9 million, a decrease of $25.4 million or 10.5% from $241.3 million in the prior year[6] - Net sales for the fiscal year ended February 1, 2026, were $565.2 million, a decrease of 9.8% compared to $626.6 million for the fiscal year ended February 2, 2025[29] - Operating income for the fiscal year ended February 1, 2026, was a loss of $10.2 million, an improvement from a loss of $36.9 million in the previous year[29] - Net income attributable to controlling interest for the fiscal year ended February 1, 2026, was a loss of $16.4 million, compared to a loss of $43.7 million in the previous year[29] Cash Flow and Liquidity - Full year positive free cash flow of $16.6 million, an improvement of $41.8 million from the prior year[4] - Free cash flow for the fiscal year ended February 1, 2026, was $16.6 million, a significant recovery from a negative free cash flow of $25.2 million in the previous year[34] - The company reported cash and cash equivalents of $16.3 million as of February 1, 2026, up from $3.3 million at the end of the previous fiscal year[31] Margins and Profitability - Gross margin increased to 53.0%, up 890 basis points from 44.1% in the prior year[7] - Gross profit for the fiscal year ended February 1, 2026, was $301.6 million, representing a gross margin of 53.3%, slightly down from 49.2% in the previous year[29] - Adjusted EBITDA for the fourth quarter increased by $8.9 million to $17.5 million compared to the prior year[4] - Forecasted adjusted EBITDA for the upcoming fiscal year is expected to range from $26 million to $30 million[39] Expenses and Liabilities - Selling, general and administrative expenses decreased by $5.3 million or 4.8% to $105.4 million[8] - The company incurred restructuring expenses of $1.2 million for the fiscal year ended February 1, 2026, compared to $7.7 million in the previous year[36] - Total liabilities decreased to $236.5 million as of February 1, 2026, from $272.8 million as of February 2, 2025[29] Sales Channels - Direct-to-consumer net sales decreased by 16.5% to $144.3 million, while retail store net sales increased by 4.7% to $71.6 million[6] Future Outlook - Fiscal 2026 outlook projects net sales in the range of $540 million to $560 million and adjusted EBITDA between $26 million and $30 million[11] - Capital expenditures for fiscal 2026 are expected to be approximately $12 million[11] - Forecasted net loss for the upcoming fiscal year is projected to be between $11.8 million and $7.5 million[39]

Financial Performance - Total sales for Q4 2025 were $112.1 million, a decrease of 6.0% from $119.2 million in Q4 2024, with comparable sales down 7.3%[4] - Net loss for Q4 2025 was $(29.6) million, or $(0.54) per diluted share, compared to a net loss of $(1.3) million, or $(0.02) per diluted share in Q4 2024[4] - Total sales for fiscal 2025 were $435.0 million, down 6.9% from $467.0 million in fiscal 2024, with comparable sales decreasing by 8.4%[4] - Adjusted EBITDA for Q4 2025 was $(1.8) million, compared to $4.2 million in Q4 2024[4] - For fiscal 2025, the net loss was $(35.9) million, or $(0.66) per diluted share, a significant decline from net income of $3.1 million, or $0.05 per diluted share in fiscal 2024[37] - Adjusted EBITDA for Q4 fiscal 2025 was $(1.8) million, down from $4.2 million in Q4 fiscal 2024; for fiscal 2025, adjusted EBITDA was $1.6 million compared to $19.9 million in fiscal 2024[40] - Gross profit for the fiscal year ended January 31, 2026, was $188.99 million, down from $217.20 million in the previous year[71] - Adjusted net income (non-GAAP basis) for the fiscal year ended January 31, 2026, was a loss of $11.5 million, or $(0.21) per diluted share, compared to an adjusted net income of $4.3 million, or $0.07 per diluted share for the previous fiscal year[76] Cash Flow and Investments - As of January 31, 2026, total cash and investments were $28.8 million, down from $48.4 million at February 1, 2025, with no outstanding debt[4] - Cash flow from operations for fiscal 2025 was $2.1 million, a decrease from $29.6 million in fiscal 2024[41] - Free cash flow before capital expenditures for store development was $(9.2) million in fiscal 2025, compared to $15.1 million in fiscal 2024[42] - Cash and cash equivalents increased to $23.81 million as of January 31, 2026, from $11.90 million as of February 1, 2025[73] - Cash flow from operating activities (GAAP basis) for the fiscal year ended January 31, 2026, was $2.1 million, a decrease from $29.6 million in the prior year[78] - Free cash flow (non-GAAP basis) for the fiscal year ended January 31, 2026, was a loss of $18.0 million, compared to a positive free cash flow of $1.9 million for the previous fiscal year[78] Operational Metrics - Gross margin for Q4 2025 was 40.8%, down from 44.4% in Q4 2024, primarily due to a decrease in merchandise margin and increased occupancy costs[21] - SG&A expenses for Q4 2025 were 42.4% of sales, compared to 41.7% in Q4 2024, with a dollar decrease of $2.2 million[26] - The impact of tariffs on merchandise margins was estimated to be approximately 110 basis points for Q4 2025 and 50 basis points for fiscal 2025[23] - Operating losses are forecasted in the near term, with an expected impact of tariffs on gross margin estimated at approximately 150 basis points if current rates remain[60] - The company plans to continue proactive measures, including vendor negotiations and cost mitigation programs, to address tariffs and trade restrictions[60] Future Outlook - The merger with FullBeauty Brands is expected to close in Q2 of fiscal 2026, projected to generate $1.2 billion in revenue and $25 million in annual run-rate cost synergies[7] - The company aims to increase private-brand penetration from approximately 57% at the start of fiscal 2025 to over 60% in fiscal 2026 and more than 65% in fiscal 2027[9] - The company expects capital expenditures for fiscal 2026 to range from $8.0 million to $12.0 million, primarily for technology-related projects[48] - The company opened eight new DXL stores during fiscal 2025 and plans to limit new store openings in fiscal 2026 due to economic headwinds[47][48] Inventory and Assets - Inventory decreased by 2.6% to $73.5 million as of January 31, 2026, compared to $75.5 million at February 1, 2025[45] - Total assets decreased from $380.96 million as of February 1, 2025, to $366.95 million as of January 31, 2026[73] Tax and Valuation - The effective tax rate for the fourth quarter was 3.1%, and for the fiscal year 2025, it was 10.7%[76] - The company established a full valuation allowance against net deferred tax assets amounting to $20.4 million for the fiscal year ended January 31, 2026[76] - Impairment of assets recorded was $1.3 million for both the three months and fiscal year ended January 31, 2026[76] Transaction Costs - The company incurred transaction-related costs of $3.6 million for the three months ended January 31, 2026[76]

Financial Performance - Fiscal 2026 net sales reached $671.3 million, a 2.7% increase from $653.4 million in fiscal 2025[4] - Operating income for fiscal 2026 was $29.8 million, up 49.0% from $20.0 million in fiscal 2025[11] - Adjusted operating income for fiscal 2026 was $34.8 million, an increase of 28.7% from $27.1 million in fiscal 2025[11] - Fourth quarter net sales were $191.6 million, reflecting a 5.6% increase from $181.5 million in the fourth quarter of fiscal 2025[7] - Fourth quarter diluted EPS was $0.55, a 52.8% increase from $0.36 in the prior-year period[7] - Net income attributable to Movado Group, Inc. for the twelve months ended January 31, 2026, was $26,552,000, compared to $18,364,000 in 2025, representing a year-over-year increase of 44.5%[21] - Diluted earnings per share for the three months ended January 31, 2026, increased to $0.55 from $0.36 in the same period last year, reflecting a growth of 52.8%[21] - Net income for the twelve months ended January 31, 2026, was $26,868 thousand, an increase of 40.1% compared to $19,209 thousand in the previous year[31] Sales Growth - The Movado brand saw a 25% sales growth in wholesale business during the fourth quarter[3] - U.S. net sales increased by 11.2% in the fourth quarter compared to the same period last year[8] - Total net sales on a constant dollar basis for the twelve months ended January 31, 2026, increased by 1.0% to $659,666,000 compared to $653,378,000 in 2025[23] Cash and Assets - The company ended fiscal 2026 with $230.5 million in cash and no debt[4] - Cash and cash equivalents at the end of the period rose to $230,541 thousand, compared to $208,501 thousand at the end of the previous year, marking an increase of 10.4%[31] - Total assets increased to $742,621 thousand in January 2026, up from $729,231 thousand in January 2025, representing a growth of 1.8%[29] - Net cash provided by operating activities was $57,921 thousand, a significant recovery from a cash outflow of $1,504 thousand in the prior year[31] - Shareholders' equity increased to $508,842 thousand, up from $481,329 thousand, reflecting a growth of 5.7%[29] Expenses and Dividends - The company reported a total operating expense of $333,774,000 for the twelve months ended January 31, 2026, slightly up from $333,125,000 in 2025[21] - Dividends paid were $31,052 thousand, consistent with the previous year's payment of $31,069 thousand[31] - Capital expenditures decreased to $4,512 thousand from $7,966 thousand, indicating a reduction in investment spending[31] Future Outlook - The company has opted not to provide a fiscal 2027 outlook due to current economic and geopolitical uncertainties[10] - The company anticipates continued growth in e-commerce and plans to focus on new product development to adapt to changing consumer preferences[20] - Movado Group, Inc. is actively managing its expenses and exploring market expansion opportunities to enhance profitability[20] Other Financial Metrics - Gross profit for the twelve months ended January 31, 2026, was $363,603,000, up from $353,140,000 in 2025, reflecting a year-over-year increase of 2.7%[21] - Operating income for the three months ended January 31, 2026, rose to $13,806,000, a significant increase from $9,222,000 in the prior year, marking a growth of 49.5%[21] - Non-operating income for the three months ended January 31, 2026, was $724,000, down from $1,554,000 in the prior year[21] - The effect of exchange rate changes contributed $8,616 thousand to cash, contrasting with a negative impact of $2,952 thousand in the previous year[31] - Total current liabilities remained relatively stable at $113,048 thousand, slightly up from $112,960 thousand in the previous year[29]